RxDoctor Payments Data

Daniel Borkert, MD

Family Medicine · Greenville, SCNPI 1285651042

Payments from drug & device makers

$9,266in general payments, 2019–2025

Across 543 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$824
  • AstraZeneca$629
  • Supernus Pharmaceuticals, Inc.$525
  • Lilly USA, LLC$517
  • Novo Nordisk$513
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$9,266100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,266 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$51,106
Medicare patients
106
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$126,866
EliquisApixaban37$42,018
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$31,998
MounjaroTirzepatide22$29,935
TrulicityDulaglutide18$29,382
MyrbetriqMirabegron30$28,180
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$26,662
JardianceEmpagliflozin17$23,217
NexlizetBempedoic Acid/Ezetimibe22$13,400
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$4,445
Levothyroxine Sodium305$2,713
Omeprazole100$2,358
Atorvastatin Calcium252$2,110
Gabapentin72$2,017
Amlodipine Besylate284$1,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$513$126,86680 claims
Lilly USA, LLCMounjaro, Trulicity$517$59,31840 claims
PfizerEliquis$405$42,01837 claims
Astellas Pharma US IncMyrbetriq$139$28,18030 claims
GSKTrelegy Ellipta$479$26,66215 claims
Boehringer IngelheimJardiance$341$23,21717 claims
Esperion Therapeutics, Inc.Nexlizet$230$13,40022 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$38$2,713305 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →